STSA News and Press, Satsuma Pharmaceuticals Inc. From 09/10/20

Gainers:  Yield10 Bioscience (NASDAQ: YTEN ) +60% . More news on: Yield10 Bioscience, Inc., Renren Inc., Virtusa Corporation, Stocks on the move, , Read more ...

Thinly traded micro cap Satsuma Pharmaceuticals (NASDAQ: STSA ) tanks  84%  premarket on robust volume in reaction to an unsuccessful Phase 3 EMERGE efficacy trial evaluating STS101 (dihydroergotamine) (DHE) as an acute treatment for migraine. More news on: Satsuma Pharmaceut...

Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration STS101 was well-tolerated in this trial with low adverse event r...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, is scheduled to present at the following conferences in the mon...

Satsuma Pharmaceuticals (NASDAQ: STSA ) : Q2 GAAP EPS of -$0.65. More news on: Satsuma Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020 Initiated patient enrollment in ASCEND™ Phase 3 open-label safety trial of STS101   ...

ASCEND results expected to support STS101 NDA filing in Q4 2021 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the initiation of patient enrollment in the ASCEND tr...

Evercore ISI has added a healthy 19 stocks in a fresh resumption of its best SMID "core" ideas this month - the research team's very best small and mid-cap stocks. More news on: Cheniere Energy, Inc., WPX Energy, Inc., Chart Industries, Inc., Notable Calls, Healthcare stocks news, Energy s...

Satsuma Pharmaceuticals ( STSA -0.3% ) appointed  industry veteran Thomas M. Soloway, currently serving as EVP and COO of Audentes Therapeutics ( BOLD ), to its board of directors, effective July 2, 2020. More news on: Satsuma Pharmaceuticals, Inc., Audentes Therapeutics, Inc., Asc...

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharmaceutical industry veteran Thomas M. Soloway to its Board of Directors effective July 2, 202...